Table 3 Results from base-case analyses
a: Overall effects [cohort of 1 million individuals not discounted] | |||||
|---|---|---|---|---|---|
|  | Number of HZ-cases | Costs of treatment (€) | Costs of vaccination (€) | Total costs (€) | BCR* |
Status quo | 284,768 | 127,978,000 | - | 127,978,000 | Â |
Vaccination scenario | 264,977 | 117,948,913 | 29,496,000 | 147,444,913 | 0.34 |
b: Number needed to vaccinate (NNV) | |||||
Avoiding one HZ-case | Â | 10 | Â | Â | Â |
Avoiding one PHN-case | Â | 144 | Â | Â | Â |
Gaining one QALY | Â | 195 | Â | Â | Â |
c: Costs and effects in both scenarios of the model | |||||
Not discounted | Costs (€) | Effects [QALY] | Costs/Effects | ICER | |
Status quo | Â | 127.98 | 29.2747 | 4.3716 | Â |
Vaccination scenario | Â | 147.44 | 29.2757 | 5.0364 | 19,002 |
Discounted | Â | Â | Â | Â | |
Status quo | Â | 82.80 | 18.8569 | 4.3911 | Â |
Vaccination scenario | Â | 98.64 | 18.8574 | 5.2307 | 28,146 |